The COVID-19 pandemic may be over, but our immune systems are still feeling the impact. After years of battling constant viral threats, from COVID-19 to seasonal flu and other infections, our body’s defense system is exhausted. Many people continue to experience lingering inflammation, frequent illnesses, and slower recovery times. This extended state of immune stress has compromised us further to chronic illness, including autoimmune diseases and even neurodegenerative diseases such as Parkinson's. So why is our immune system still in trouble? And how do we give it its power back? Understanding immune exhaustion is the beginning of rebuilding our body's natural immunity.
A weakened immune system makes people more susceptible to disease, mental illnesses, and even sleep disorders. Now, new research indicates that immune system depletion may play an important role in the onset of Parkinson's disease, a degenerative neurologic disorder that compromises movement and cognition.
Dysfunctional immune response is a leading cause of long-standing inflammation within the body, that has been found to contribute towards a multitude of conditions, including cardiovascular conditions, diabetes, depression, and neurodegenerative diseases such as Alzheimer's.
As people age, their immune system naturally becomes less effective. This deterioration, referred to as immune exhaustion, may be a key contributor to the onset and progression of Parkinson’s disease. Rebecca Wallings, a Parkinson’s Foundation Launch Award grant recipient and senior postdoctoral fellow at the University of Florida, believes that an accumulation of exhausted immune cells could be driving neurodegeneration in Parkinson’s patients.
Parkinson's disease is most commonly linked with the degeneration and loss of dopaminergic neurons—motor nerve cells that produce dopamine, an essential neurotransmitter for movement. While researchers have long suspected inflammation is involved in this neurodegeneration, the mechanisms are not yet well understood.
Wallings' study is on immune cell exhaustion, a process by which aging immune cells fail to control immune responses effectively. Her research indicates that instead of dampening inflammation in Parkinson's patients, attempts should be made to rejuvenate the immune system to regain its functionality.
One of the major findings of Wallings' work is the function of mitochondrial impairment in immune cell exhaustion. Mitochondria are commonly called the powerhouses of cells, as they are vital for generating energy. As mitochondria age and become inefficient, immune cells fail to function well, potentially accelerating neurodegeneration in Parkinson's disease.
Wallings has found that mutations in the LRRK2 gene, a recognized genetic risk factor for Parkinson's disease, are linked with defective mitochondrial function and immune cell exhaustion. Her current work includes testing various therapeutic approaches to restore mitochondrial function in immune cells with the potential to enhance the immune system and potentially prevent or treat Parkinson's disease.
For decades, the standard practice in treating Parkinson's has been to suppress brain inflammation. Yet Wallings' work indicates that instead of slowing down immune responses, restoring the immune system could be a more successful strategy. By addressing mitochondrial impairment and immune resilience, researchers can potentially reverse or slow down Parkinson's disease.
Wallings is now looking into how to rejuvenate immune cells by fixing mitochondria. She studies immune cells from patients with Parkinson's as well as from healthy subjects and performs experiments on animal models to determine if rejuvenation of the immune system could result in improved disease outcomes.
While there is no cure for Parkinson's disease, some lifestyle adjustments may decrease the chances of developing the illness. Since neurodegenerative diseases are associated with chronic inflammation and immune dysfunction, developing habits that enhance immune function might prove helpful.
Diet: There is evidence to suggest that eating in accordance with the Mediterranean or MIND diets, both high in antioxidants, healthy fats, and anti-inflammatory foods, can encourage brain wellness and reduce Parkinson's risk.
Avoiding Dangerous Substances: Restricting alcohol and nicotine use can maintain a robust immune system and suppress inflammation.
Reducing Stress: Chronic stress weakens immune function, so methods such as meditation, exercise, and sufficient sleep can lead to improved overall well-being.
Credit: AI generated image
Many people carry the thalassemia gene without knowing it because they may not have any symptoms. A simple carrier screening test before pregnancy can help couples understand risks and make informed decisions while planning parenthood.
Parenthood planning today is not only about financial preparation or healthy lifestyle changes, but also about understanding genetic health risks that can impact the child’s future. And one such condition that tends to go unnoticed is thalassemia carrier status.
Did you know? Many individuals discover they are carriers only after facing difficulties during pregnancy or after the birth of a child with thalassemia major.
Thalassemia is an inherited blood disorder that affects the production of hemoglobin, the protein in red blood cells that carries oxygen throughout the body. People who are carriers usually live normal and healthy lives and may not experience major symptoms. Because of this, many remain unaware of their carrier status for years.
However, it becomes a matter of concern when both partners are carriers of the thalassemia gene. In such cases, there is a huge risk that the child may inherit thalassemia major, a severe condition that may require lifelong blood transfusions, regular hospital visits, medications, and continuous medical care.
These are some of the challenges faced by families: So, challenges are that the thalassemia carrier status is often detected very late. Mild tiredness or anemia may be ignored or mistaken for iron deficiency, and many will not seek help.
So, couples do not consider genetic testing before marriage or pregnancy because they feel healthy and have no family history of the disease. When a child is born with thalassemia major, families may face stress, anxiety, repeated hospital visits, financial burden, and long-term treatment responsibilities. The condition can also affect the child’s growth, immunity, and overall quality of life.
This is why screening is important for couples: Carrier screening is a simple blood test that helps identify whether a person carries the thalassemia gene. If one partner tests positive, the other partner is advised to get tested as well.
Early screening before pregnancy helps couples understand their risks and explore available options with proper guidance. Thalassemia carrier screening is a small step that can make a major difference in parenthood planning.
Increasing awareness and encouraging timely testing can help families make informed decisions and reduce the burden of severe thalassemia in future generations. So, it is imperative to go for timely screening as advised by the expert and improve the quality of life.
Credit: iStock
Mental health issues among doctors remain a serious but rarely discussed concern within the medical community, said Dr. Cyriac Abby Philips, popularly known on social media as the LiverDoc.
In an exclusive interaction with HealthandMe, the noted hepatologist highlighted the rising cases of burnout, depression, and suicide among healthcare professionals and the urgent need to address them.
He stated that doctors are among the major communities affected by mental health disorders, although the topic is often ignored within the profession.
“We have had very senior doctors die by suicide because of burnout,” he said, citing incidents involving highly successful doctors recently reported from parts of India, including Kerala.
Liver Doc stressed that addressing doctors’ mental health is as important as treating patients’ mental health.
“A doctor who has good mental health will be a much better ally for the patient when it comes to treatment,” he said.
He also urged the medical community and regulatory authorities to introduce more interventions and support systems to prevent burnout and mental health disorders among doctors.
According to him, the emotional burden of treating critically ill patients and witnessing deaths regularly can deeply affect healthcare professionals.
“It’s depressing to treat patients and see them die. It’s depressing to see another human die,” he said.
The expert noted that doctors should find ways to openly discuss and process emotional stress and mental health struggles.
Dr. Philips also addressed the issue in his recently released book, The Liver Doctor: Stories of Love, Loss and Regeneration.
He told HealthandMe that he has “very thoroughly and in very raw format addressed in the book” the mental health disorders affecting doctors, as it directly impacts patient care.
“Like every other doctor, I have also gone through that, and it's depressing to treat patients and see them die. I have this book to channelize that, and I feel less burdened when I do that, but other doctors also should find ways to do this. So this book also tells doctors to be more open about their mental health,” he said.
Doctors in teaching hospitals often endure long, unregulated shifts with little time for rest, especially during residency. Such exhausting work conditions not only increase the risk of medical errors but also significantly contribute to burnout, emotional exhaustion, and mental health problems among young doctors.
As per a recent nationwide survey on doctors’ mental health and morale, nine in ten doctors said they would not want their children to become physicians.
Also read: Global Mental Disorders Double In 33 Years, Affecting 1.2 Billion People: Study
The study, conducted by the Debabrata Mitalee Auro Foundation, surveyed 1,208 doctors across metropolitan cities and smaller towns over six months and found deep levels of burnout, fear of violence, and rising medico-legal anxiety among medical professionals.
Further, the Parliamentary Standing Committee on Health and Family Welfare also raised concerns over “excessive continuous duty hours” for junior and senior resident doctors in April.
In its latest report, the panel warned that fatigue-driven errors and burnout could compromise care.
The Panel recommended that the government introduce and strictly enforce a formal “Clinical Duty Hours Regulation” policy. This would mandate fixed rest periods and monitored duty rosters, with oversight mechanisms to prevent violations.
Credit: iStock
India’s cell and gene therapy ecosystem is beginning to attract a different kind of attention that is driven not just by healthcare demand, but by proprietary science and platform-led innovation.
For investors, however, the larger story may not be the funding round itself. It may be the problem the company is trying to solve.
CAR-T therapies have transformed outcomes for several difficult-to-treat blood cancers globally. But despite strong initial responses, relapse remains one of the field’s biggest limitations. One reason is antigen escape, which means cancer cells can change the markers that therapies use to identify them, making them harder to detect over time.
In an analysis of 4,129 CAR-T treated patients, relapse remained a substantial issue after single-target therapy, with 42.1% of relapses associated with loss of the CD19 target itself. The finding points to a larger issue: precision may not be enough if therapies lose visibility over time.
The response increasingly appears to be a move toward multi-target and more durable platforms. A bispecific CAR-T platform designed to recognize more than one tumor marker, to reduce relapse is crucial.
The science itself is becoming increasingly platform-oriented. Beyond broader targeting, recent work explored why immune cells themselves lose effectiveness over time and identified pathways associated with stronger persistence and memory. While still early, the broader implication is that future therapies may need to be designed not only to attack disease, but also to remain active longer.
For India, that creates a larger opportunity. Historically, advanced therapies such as CAR-T have remained expensive and heavily dependent on technologies developed elsewhere. The aim is to significantly reduce treatment costs while building indigenous capabilities across design and manufacturing.
The shift matters because biotech investing is increasingly moving beyond services and generics toward intellectual property and platform science. The transition from bedside observations to translational platforms may be where the next phase of healthcare innovation and investment gets built.
© 2024 Bennett, Coleman & Company Limited